Best Transcriptomics Podcasts (2025)

1
Busulfan-melphalan conditioning in newly diagnosed, transplant-eligible multiple myeloma; and use of spatial transcriptomics to probe the three-dimensional properties of multiple myeloma bone marrow microenvironments ... 13:13

Play Pause

16d ago13:13

13:13

In this week's episode we’ll learn more about a study comparing busulfan-melphalan with melphalan alone as the conditioning protocol for newly diagnosed, transplant-eligible multiple myeloma; then we will discuss data on how three-dimensional transcriptomics can reveal complex interactions between plasma cells and bone marrow microenvironments. Fea…

1
Radiotherapy induced neurocognitive decline 16:05

6d ago16:05

16:05

Description: Dr. Iyad Alnahhas interviews Dr. Charlotte Sleurs about her and her team's recent manuscript entitled: "Radiotherapy-induced neurocognitive decline among adult intracranial tumor patients: A voxel-based approach", published online in Neuro-Oncology in May 2025.By Drs. Iyad Alnahha and Charlotte Sleurs

1
Breakthroughs in Multiple Myeloma Treatment and Von Willebrand Disease Mechanisms 24:11

7d ago24:11

24:11

In this week's episode of the Blood Podcast, Associate Editor Dr. James Griffin interviews Drs. Binod Dhakal and Ruben Bierings about their respective papers published in this week's issue of Blood. Dr. Dhakal presents his study on using talquetamab, a bispecific antibody, as a bridging therapy before BCMA-targeted CAR T-cell therapy in multiple my…

1
Spotlight on Acute Myeloid Leukemia 21:39

14d ago21:39

21:39

In this Spotlight series episode on Acute Myeloid Leukemia, Blood Editor, Dr. Selina Luger interviews Drs. Laura Michaelis and Alexander Perl on their paper in the series titled “The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment”. The conversation explores challenges in treating AML…

1
How I Treat Wiskott-Alrich syndrome 13:16

28d ago13:16

13:16

In this How I Treat podcast episode, Laura Michaelis, MD interviews Sung-Yun Pai, MD about their recently published article in Blood journal "How I treat Wiskott-Alrich syndrome". They highlight recent updates in treatment, including new risk-benefit calculations due to safer treatments and longer follow-ups. Challenges include late diagnosis, lack…

1
Use of Marstacimab for Prophylaxis in hemophilia A and B; matched-donor allogeneic CD19 CAR-T in adult B-ALL; a new prognostic index for T-cell cutaneous lymphomas 19:43

28d ago19:43

19:43

In this week's episode we'll learn about targeting the tissue factor pathway inhibitor with a monoclonal antibody to rebalance HEMOSTASIS in hemophilia A and B. In the phase 3 BASIS trial, the monoclonal antibody marstacimab reduced bleeding events, and was generally well tolerated, with no unanticipated side effects. After that: matched-donor allo…

1
QOL and cognitive functioning in patients with oligodendroglioma 18:22

1M ago18:22

18:22

Dr. Iyad Alnahhas interviews Drs. Florien Boele and Martin Klein about their recent manuscript entitled: "Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation", published online in Neuro-Oncology in July 2025.By Drs. Iyad Alnahhas, Florien Boele, Martin Klein

1
Epstein-Barr virus genomic variants in human disease states, somatic GATA1 mutations and leukemia in Down syndrome, and new definitions for high-risk multiple myeloma 18:01

1M ago18:01

18:01

In this week's episode, we’ll learn more about relationships between Epstein-Barr virus genomic variants and human diseases, including hematological malignancies; the presence and timing of somatic GATA1 mutations and their relationship to a Down syndrome-specific form of leukemia; and new definitions for high-risk multiple myeloma that emphasize t…

1
Review Series on Acute Lymphoblastic Leukemia (ALL) 12:38

1M ago12:38

12:38

In this Review Series episode, Associate Editor Dr. Hervé Dombret speaks with Dr. Mark Litzow about the latest immunotherapy advances for Acute Lymphoblastic Leukemia (ALL). The discussion highlights innovative treatments like blinatumomab and inotuzumab, which are showing remarkable success in clinical trials, including an 85% three-year survival …

1
Azacitidine holds promise in VEXAS syndrome; a step forward in precision blood matching; identifying a new vulnerability in TP53-mutated AML 18:58

1M ago18:58

18:58

In this week's episode we'll learn about Azacitidine in VEXAS syndrome. Treatment can provide responses in patients with this complex autoinflammatory disorder. But relapse rates were high, so long-term therapy may be required to maintain disease control. After that: A step forward in precision blood matching. High-throughput array genotyping enabl…

1
Post-operative radiation in recurrent grade 1 meningiomas 19:39

2M ago19:39

19:39

Dr. Iyad Alnahhas interviews Drs. Felix Sahm and Maximilian Deng about their recent manuscript entitled: "Postoperative radiotherapy in subtotally-resected recurrent WHO grade 1 meningiomas with intermediate/ high-risk molecular profiles", published online in Neuro-Oncology in May 2025.By Drs. Felix Sahm, Maximilian Deng, Iyad Alnahhas

1
Diffuse large B-cell lymphoma’s long-term effects on immune profiles, plasminogen activation and prevention of venous thromboembolism, and PARP inhibitors in hematological malignancies carrying epigenetic ... 18:31

2M ago18:31

18:31

In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that make…

1
“Ironing out” Tet2-mutant HSPCs; A CAR-T “license to kill” in T cell leukemia/lymphoma; insights on cHL genetics, through the lens of ctDNA 20:43

2M ago20:43

20:43

In this week's episode, we'll learn about how TET2 is often mutated in myeloid malignancies and clonal hematopoiesis. In new work, expansion of Tet2-mutant HSPCs was dependent on Ncoa4, the cargo receptor mediating ferritinophagy. We’ll iron out the implications. After that: a double-oh-seven license to kill in T-cell leukemia/lymphoma. WU-CART-007…

1
mRNA CAR T against GD2 in high-grade glioma models 29:43

2M ago29:43

29:43

Dr. Maya Graham interviews Dr. Jessica Foster about her and her team's recent manuscript, entitled "Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models". This work was published online in Neuro-Oncology in May 2025.By Drs Maya Graham, Jessica Foster, Iyad Alnahhas

1
Targeting NPM1 in AML with a menin inhibitor; in primates, a CD137 ADC eliminates acute GVHD 15:10

2M ago15:10

15:10

In this week's episode we'll learn about targeting NPM1 in acute myeloid leukemia. Researchers report the first clinical evidence of a menin inhibitor inducing complete remissions in AML with a NPM1 mutation. This validates NPM1 as a new therapeutic target in AML, alongside FLT3, IDH1/2, and KMT2A. Also on the podcast: targeting CD137 to prevent gr…

1
How I Treat Series on Iron Overload in Hematologic Disorders 34:17

2M ago34:17

34:17

Blood Editor, Dr. Thomas Coates interviews Dr. Emanuele Angelucci on his paper, "How I manage iron overload in the hematopoietic cell transplantation setting" which is featured in Blood's "How I Treat Series on Iron Overload in Hematologic Disorders". See the full How I Treat series in volume 145 issue 4 of Blood.…

1
Early prediction of follicular lymphoma patients with poor survival; immune hotspots in aplastic anemia; role of allo-transplant for Hodgkin lymphoma in the checkpoint inhibitor era 19:49

2M ago19:49

19:49

In this week's episode we'll learn about how by combining PET response with circulating tumor DNA, or ctDNA, in newly treated patients with follicular lymphoma, investigators identify those patients likely to progress within 24 months of initial treatment, also known as POD24. After that: Immune hotspots in aplastic anemia. These newly identified h…

1
Exogenous CD19 stimulation in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy, sequential rapid immune-assay in heparin-induced thrombocytopenia diagnosis, and new survival prediction ... 18:42

2M ago18:42

18:42

In this week's episode, we’ll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy; new algorithms that incorporate sequential rapid immune-assays, intended to improve diagnosis of heparin-induced thrombocytopenia, and resource-adaptive survival pr…

1
How I Treat series on Acute Myeloid Leukemia 42:55

3M ago42:55

42:55

In this episode, Associate Blood editor Dr. Selina Luger leads a discussion with Drs. Courtney DiNardo, Eunice Wang, Andrew Wei and Gail Roboz about the advances in treatment options for Acute Myeloid Leukemia (AML). The conversation highlights new combinations like Venetoclax-azacitidine, challenges with differentiation syndrome, and emerging stra…

1
Daratumumab maintenance in newly-diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in myeloproliferative neoplasms; and novel genetic loci associated with the risk of heavy menstrual ... 15:11

3M ago15:11

15:11

In this week's episode, we’ll learn more about the effects of daratumumab maintenance on minimal residual disease in patients with newly diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in the pathophysiology of myeloproliferative neoplasms; and a genome-wide association study that identified novel genetic loci associated wi…

1
Hematopoietic stem cells with enhanced transplantability, ruxolitinib for refractory macrophage activation syndrome, and magrolimab in newly diagnosed acute myeloid leukemia 18:56

3M ago18:56

18:56

In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still’s disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leuke…

1
A JAK inhibitor for CRS and ICANS prevention; ChAdOx1-platelet interactions and post-vaccination arterial thrombosis; lineage switch, an emerging mechanism of leukemia relapse 18:51

3M ago18:51

18:51

In this week's episode, we'll learn about a JAK inhibitor to prevent complications of CD19-directed CAR T-cell therapy. In a phase 2 study, itacitinib was well tolerated and demonstrated promising reductions in the incidence of cytokine release syndrome and neurotoxicity. After that: investigators report direct interactions between ChAdOx1 and plat…

1
Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with ... 18:53

3M ago18:53

18:53

In this week's episode we’ll learn more about the use of ruxolitinib plus dexamethasone to treat newly diagnosed patients with adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors as a potential new class of therapies for sickle cell disease and other beta-globinopathies; and insights into clinical characteristics of p…

1
Review series on mantle cell lymphoma 17:14

3M ago17:14

17:14

In this episode, Associate Editor Dr. Philippe Armand discusses the Review Series on mantle cell lymphoma with author Dr. Christine Ryan. Both were authors of "Frontline management of mantle cell lymphoma", and discuss shifts in treatments and new research. Find the full review series in Volume 145 Issue 7 of Blood: "Review series on mantle cell ly…

1
A transcriptomic atlas of CNS tumors 35:22

4M ago35:22

35:22

Dr. Evan Noch interviews Dr. Akshitkumar Mistry about his and his team's recent manuscript entitled "A clinically annotated transcriptomic atlas of nervous system tumors", published online in Neuro-Oncology in May 2025 Link to the paper: https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf130/8151442…

1
Rapid, high-sensitivity ADAMTS13 assays for TTP; combination CD38/PD-1 blockade in extranodal NK/T-cell lymphoma; a “zombie enzyme” in CREBBP-mutant lymphomas 20:08

4M ago20:08

20:08

In this week's episode, we'll learn about rapid, high-sensitivity diagnostic assays for TTP, or thrombotic thrombocytopenic purpura, that can reduce unnecessary treatments. After that: enhancing PD-1 blockade in relapsed/refractory extranodal NK/T-cell lymphoma. In a single-arm, phase 2 study, combined CD38 and PD-1 inhibition demonstrated durable …

1
Wenqing Li on transcriptome risk scores to decipher susceptibility genes for risk stratification of gastric cancer 21:18

4M ago21:18

21:18

Dr. Wenqing Li joins Peng Zhang to discuss a recent study integrating genetics and transcriptomics for risk stratification of gastric cancer. The conversation explores the global epidemiology of gastric cancer, its high prevalence and mortality rates, particularly in East Asia and China, and the complex interplay of genetic and environmental risk f…

1
A novel mouse model of sickle cell SC disease; multiple myeloma induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone; and splicing factor mutations in myelodysplastic syndromes ... 19:08

4M ago19:08

19:08

In this week's episode we’ll learn more about a novel mouse model that recapitulates many of the properties of human sickle cell SC disease; results from the induction phase of the risk-adapted MIDAS trial of isatuximab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma; and a link between splicin…

1
Gut microbiome in primary CNS lymphoma 15:04

4M ago15:04

15:04

Dr. Iyad Alnahhas interviews Drs. Isaias Hernandez-Verdin and Agusti Alentorn about their recent manuscript entitled: "Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: An ancillary study from the BLOCAGE trial", published online in Neuro-Oncology in March 2025 Link: https://academic.o…

1
An AI model for transplant risk in myelofibrosis; preventing priapism in men with sickle cell anemia; hallmarks of T cell exhaustion absent in newly diagnosed MM 18:24

4M ago18:24

18:24

In this week's episode, we'll learn about using AI to assess transplant risk in myelofibrosis. In a step toward personalized medicine, researchers report on a machine learning model that identifies 25% of patients with poor outcomes. After that: preventing priapism in men with sickle cell anemia. A recent phase 2 feasibility study shows high rates …

1
Social determinants of health and access to allogeneic hematopoietic cell transplantation, megakaryocyte growth factor receptor-based pretransplant conditioning for ex vivo autologous gene therapy, and ... 19:38

4M ago19:38

19:38

In this week's episode, we’ll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, or AML; use of megakaryocyte growth factor receptor-based stem cell depletion as part of pretransplant conditioning in ex vivo autologous gene therapy; and identifi…

1
Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets 41:28

4M ago41:28

41:28

Blood editor Dr. Laurie Sehn discusses the topic of "Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets" featuring Drs. Mark Roschewski, Grzegorz Nowakowski, and Neha Mehta-Shah, who each contributed to the articles featured in the review series on high-risk aggressive lymphoma. See the full review series on high risk lymphoma…

1
A key role for T-cell TET3 in chronic GVHD; a BTK inhibitor for ITP; co-inhibition of pre-TCR and IL-7R pathways in a T-ALL patient subset 20:30

5M ago20:30

20:30

In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immunoglobulin class switching and suppressed lung fibrosis. Accordingly, TET3 may be a new therapeutic target in chronic GVHD. After that: rilzabrutinib, a BTK inhibitor for ITP. In a randomized, placebo-c…

1
Special Episode: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma 9:47

5M ago9:47

9:47

In this special episode, Dr. Shaji Kumar from the Mayo Clinic speaks with Blood editor Dr. Laurie Sehn on a paper recently published in Blood, "Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma". The findings demonstrate eliminating the need for sequential confirmation of response in multiple myeloma. The study, invol…

1
Germline analysis of diffuse midline glioma 29:55

5M ago29:55

29:55

Dr. Evan Noch interviews Dr. Marion Mateos about her and her team's recent manuscript entitled: "Germline analysis of an international cohort of pediatric diffuse midline glioma patients", published online in Neuro-Oncology in March 2025.By Drs. Evan Noch, Marion Mateos, Iyad Alnahhas

1
How I Treat Series on Geriatric Hematology 17:19

5M ago17:19

17:19

In this How I Treat Series episode Dr. Thomas Ortel leads a discussion with author Dr. Patrick Foy on his paper “How I diagnose and treat thrombocytopenia in geriatric patients”. See the full How I Treat series on geriatric hematology in volume 143 issue 3 of Blood Journal.By American Society of Hematology

1
Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance 16:06

5M ago16:06

16:06

In this week's episode, we’ll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics, cyclophosphamide as a treatment for non-immune effector cell-associated neurotoxicity in patients treated with B-cell maturation antigen, or BCMA, targeted CAR T-cell therapies, and how differences …

1
New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE 19:46

5M ago19:46

19:46

In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: …

1
How I Treat Transfusion Medicine (part 2) 33:57

5M ago33:57

33:57

In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie Callium, Keyvan Karkouti, and Ron George. Find the full published review series in Volume 145 Issue 20 of Blood Journal.By American Society of Hematology

1
Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19 ... 20:57

5M ago20:57

20:57

In this week's episode we’ll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acut…

1
The proteomic landscape of diffuse midline glioma 16:55

6M ago16:55

16:55

Dr. Iyad Alnahhas interviews Drs. Cynthia Hawkins and Arun Vadivel about their recent manuscript entitled: "The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases", published online in Neuro-Oncology in February 2025. More Information…

1
How I Treat Transfusion Medicine (part 1) 32:12

6M ago32:12

32:12

In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on Transfusion Medicine. Topics include noninvasive prenatal testing for red blood cell and platelet antigens, transfusion cases in sickle cell disease, and pregnant patients who are alloimmunized to RB…

1
Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT 18:15

6M ago18:15

18:15

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differe…

1
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease 19:58

6M ago19:58

19:58

In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickl…

1
Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature 18:12

6M ago18:12

18:12

In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first to fully characterize hematopoietic stem and progenitor cells in the adult human lung. After that: researchers develop a neural network-based probabilistic classifier, DLBclass, that assigns all diffu…

1
Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell ... 19:06

6M ago19:06

19:06

In this week's episode we’ll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients wit…

1
Radio-Pathomic maps and MR perfusion 20:25

6M ago20:25

20:25

Dr. Iyad Alnahhas interviews Dr. Peter LaViolette about his and his team's recent manuscript entitled: "Multi-Site Retrospective Analysis of Diffusion and Perfusion MRI Correlates to Glioma Characteristics Derived from Radio-Pathomic Maps", published online in Neuro-Oncology in February 2025.By Drs. Iyad Alnahhas, Peter LaViolette

1
How I Treat Myeloproliferative Neoplasms 38:36

7M ago38:36

38:36

In this How I Treat series episode Blood Associate Editor, Dr. Jason Gotlib speaks with Drs. Aaron Gerds, Andreas Reiter, and Claire Harrison. The conversation focuses on the work and contributions of these authors to How I Treat Myeloproliferative Neoplasms, and exciting advances in the treatment and management of MPNs. See the full How I Treat se…

1
The decline of transplant for relapsed myeloma; DDAVP response in bleeding disorders; dual DOT1L/EZH2 targeting in DLBCL 18:49

7M ago18:49

18:49

In this week's episode we'll learn about the role of autologous transplant for relapsed myeloma. In an updated analysis of the GMMG ReLApsE trial, salvage autologous transplant offered no survival benefit compared to control chemotherapy. These findings may have clinical implications in an era of alternative, and highly effective, treatment options…

1
SIPs with Standards 21:00

7M ago21:00

21:00

Stable Isotope Probing (SIP) is a powerful technique for studying microbial communities. These experiments can show which microbes are handling specific nutrients, or what they're doing with those nutrients, and even how quickly. But there's a catch: SIP labwork and analysis can be very demanding. The JGI offers SIP analysis to make these experimen…